RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Drugmakers agreed to cut prices by around 50% on average for more than 100 medicines in order to have them included in China’s state medical insurance scheme from March, potentially heralding a massive leap in sales.
Novartis is seeking to repurpose the company’s investigational oral spinal muscular atrophy (SMA) medicine branaplam to treat Huntington’s disease, as the Swiss drugmaker plans a clinical trial after winning U.S. orphan drug designation.
Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).
Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.
A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.
A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.
Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.